Thanks @David_Martin for sharing article, it is helpful.
After the research from UK the benefits of Dexamethasone , our institution is also planning to start the same
I have reviewed the preprint from the RECOVERY trial. I am surprised that based on that data IDSA and SCCM are recommending dexamethasone in COVID-19 ARDS. Our institution has added it as a “consideration”. The data is clearly not strong enough to recommend. There is clear data to recommend AGAINST steroids in COVID-19 if patients are not on oxygen therapy. Due to dexamethasone shortages and concerns from our peds oncology colleagues about availability for them, we are recommending alternatives to dexamethasone if one is considering steroids for ARDS.